News

NEO-PV-01 is a personalized vaccine designed specifically for each patient based on the neoantigen mutations unique to that patient’s tumor DNA. The IND enables Neon Therapeutics to initiate

The CRL did not cite any concerns with the clinical safety and efficacy data for RI-002 submitted by ADMA in the BLA, nor has the FDA requested any

The gene and cell therapy group recently established and commissioned a second specialist bioprocessing clean room suite at Harrow House and at its new laboratories at Windrush Court

Under the terms of the agreement, Profil Institute will provide clinical research and development services, from IND readiness through the completion of early phase development, including regulatory and

The approval of Adlyxin reaffirms our continued commitment to addressing the challenges faced by people living with diabetes when trying to reach and maintain their individual blood glucose

Under the agreement, Codexis employed its CodeEvolver protein engineering platform technology to develop a novel enzyme for use in its partner’s preclinical therapeutic development program.  “We exceeded the performance

Oncolytic viruses are viruses engineered to kill cancer cells while sparing healthy cells, which subsequently elicits anti-cancer immune responses. This collaboration in oncolytic virus development adds another novel

The investment will go to sites at Barnard Castle, Durham; Montrose in Angus, Scotland; and Ware in Hertfordshire. At Barnard Castle, the company will spend £92m on a sterile facility to support the manufacture of

As per the agreement, the Chinese firm will buy all of the Gland Pharma shares owned by KKR Floorline Investments apart from the shares purchased from the company's other shareholders.